Thrombocytopenia associated with second-line carboplatin-based chemotherapy for ovarian, fallopian tube, and primary peritoneal cavity cancers

[1]  Robert S Mannel,et al.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  V. Torri,et al.  Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial , 2003, The Lancet.

[3]  I. Tannock,et al.  Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial , 2002, The Lancet.

[4]  M. Johnston,et al.  Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. , 2002, Gynecologic oncology.

[5]  E. Venkatraman,et al.  Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  H. Hansen,et al.  Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. , 2001, Gynecologic oncology.

[7]  M. Franchi,et al.  Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer. , 2001, Gynecologic oncology.

[8]  F. Mayer,et al.  High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC). , 2000, Gynecologic oncology.

[9]  M. Bookman,et al.  Second-line treatment of ovarian cancer. , 2000, The oncologist.

[10]  M. Gore,et al.  Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Rose,et al.  Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Markman,et al.  Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens. , 1997, Gynecologic oncology.

[13]  J. Berek,et al.  Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  C. Runowicz,et al.  Clinical impact of chemotherapy-induced thrombocytopenia in patients with gynecologic cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Langenberg,et al.  Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  K. Nielsen,et al.  Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.